Highlights Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 21:00:00 20/06/2024 BST			5-day change	1st Jan Change
48.92 ^USD	-1.47%		-2.36%	+6.93%

06-12	Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	MT
06-12	Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan	06-12	MT
Belite Bio, Inc. Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan	06-12	CI
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Belite Bio's Q1 Loss Narrows	05-14	MT
Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting	05-06	CI
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	03-22	CI
ADRs End Higher, ATRenew Inc. Climbs 26.9%	03-12	DJ
Belite Bio's Q4 Loss Narrows	03-12	MT
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Belite Bio Gets Clearance to Launch Tinlarebant Phase 3 Trial for Eye Disease in China	12-27	MT
Belite Bio, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Belite Bio's Q3 Loss Widens	11-14	MT
Belite Bio, Inc. Presents Results from a 24-Month, Phase 2 Study of Tinlarebant in Childhood-Onset Stargardt Disease at the AAO Annual Meeting	11-06	CI
Belite Bio, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga	27/07/23	CI
Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease	24/07/23	CI
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Belite Bio Finalizes Study Design for Late-Stage Trial of Tinlarebant to Treat Geographic Atrophy Associated with Dry AMD	18/11/22	MT
Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)	18/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Belite Bio, Inc

Equities

BLTE

US07782B1044

Highlights

Filters